DIA: Driving Insights to Action
Science:Life Sciences
“The pandemic had a substantial impact on community understanding of clinical trials. Having said that, the sort of ambient level of community knowledge of clinical trials is still substantially lower than it needs to be,” explains Australian Clinical Trials Alliance Board Chair Steve Webb. “Community awareness of the difference between evaluation of experimental interventions, about which relatively little is known regarding safety and effectiveness, compared with comparative effectiveness research, is an important distinction often with limited understanding in the community, in government, and amongst policymakers.”
Need for Value Creates Opportunity for Patients
Can Europe Optimize Healthcare Quality AND Pricing?
Rules for Successful Patient-Industry Engagement
Multiple Channels Can Share “One Medical Voice”
Advertising & Promotion: What You Can (and Can’t) Say
Could Precision Medicine Deliver “You on a Chip”?
“Enlightened Regulation” Illuminating Translational Science
Time and Place for Innovation in a Pandemic Outbreak?
SFDA Talks Drug Pricing & Shortages in Advance of MERC 2017
Translating Medical Information into Effective Communication
Tufts eClinical Study: Complexity Overrunning Technology
Post-Brexit PV in Europe “An Issue We Shouldn’t Underestimate”
CDER Director: Interest in How Patients Feel & Function
EU Clinical Trial Regulation Streamlines to "Matter of One"
The Gaps In Drug Pricing
Biosimilars’ Good News for Patients
Pace of Innovation vs. Regulation: Combination Challenge
Oligonucleotides Driving Personalized Medicine Research
Celebrating 150 Years with Better Care for Canadians
Future Science & Drug Review: FDA Closing the Gap
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Speaking of Psychology
Stuff To Blow Your Mind